672P - Cardiotoxicity of trastuzumab in the patients with HER2 positive advanced gastric cancer

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Gastric Cancer
Presenter Minkyu Jung
Citation Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371
Authors M. Jung1, J.S. Park1, C. Lee1, J.H. Kim1, H.S. Park1, S.J. Heo1, S.H. Beom1, H.S. Kim1, S.Y. Rha1, H.C. Chung1, J. Youn2
  • 1Internal Medicine, Yonsei Cancer Center, 120-752 - Seoul/KR
  • 2Internal Medicine, Yonsei University College of Medicine Department of Internal Medicine, 120-752 - Seoul/KR

Abstract

Background

Trastuzumab induced cardiotoxicy (TIC) is a main adverse event that limits the using of trastuzumab in HER2 positive breast cancer patients. However, the incidence and risk factors of TIC are still not known in HER2 positive gastric cancer. Therefore, we evaluated the incidence and predictive factors of TIC in gastric cancer patients treated with trastuzumab in clinical practice.

Methods

We retrospectively reviewed the cardiac dysfunction in HER2 positive gastric cancer between December 2005 and April 2015 through prospectively collected data base at Yonsei Cancer Center, Republic of Korea. TIC was defined as an absolute decline of at least 10 percentage points from the baseline to a value less than 55% identified by MUGA scan or echocardiogram.

Results

Among 87 patients, 54 patients (62%) received trastuzumab combination chemotherapy, and 33 patients (38%) did chemotherapy alone as first line chemotherapy. Symptomatic heart failure was not observed in both groups, and asymptomatic significant LVEF drop was developed 3 (5.6%) in trastuzumab combination group and 1 (3.3%) in chemotherapy only group (hazard ratio [HR], 1.810; 95% confidence interval [CI], 0.188-17.43; P = 0.607). Among baseline characteristics, age older than 70 years (HR, 15.0; 95% CI, 1.18-191.6; P = 0.037) was the only significant associated factor with TIC.

Conclusions

TIC in gastric cancer patients seems to be not higher than breast cancer patients. However, asymptomatic LVEF drop should be continued surveillance in HER2 positive gastric cancer patients treated with trastuzumab, especially in elderly patients.

Clinical trial identification

Legal entity responsible for the study

Minkyu Jung

Funding

Yonsi University

Disclosure

All authors have declared no conflicts of interest.